医薬品リファレンス
Zanidatamab
Zanidatamab is a medicine in the class oncology. It is used for biliary tract cancers.
- 薬効分類: Oncology
- 効能・効果: biliary tract cancers
最終更新日 出典: US FDA label, EMA SmPC
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01FD07
- 一般的な剤形
- 注射剤
- 一般的な規格
- 50 mg/ml
- 既知の相互作用
- 1 (中等度: 1)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
Bispecific HER2-directed antibody binding extracellular domains 2 and 4 of HER2, causing clustering, internalization and receptor reduction; induces CDC, ADCC and ADCP, leading to tumor growth inhibition and cell death.
成人の通常用量（添付文書の要約）
GEA, patients <70 kg: 1,800 mg IV every 3 weeks or 1,200 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr; until disease progression or unacceptable toxicity
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm; not recommended during pregnancy. HER2-directed antibodies have caused oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death.
- 授乳
- Unknown No data on presence in human milk or effects on infant. Weigh benefits of breastfeeding against clinical need; consider half-life of about 24 days and 4-month washout.
報告されている副作用
- Diarrhea
- Nausea
- Decreased appetite
- Vomiting
- Hypokalemia
- Fatigue
警告（枠囲み警告）
- With fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life-threatening and fatal cases. Use antidiarrheal prophylaxis in the first cycle; interrupt, reduce dose or discontinue based on severity. Exposure during pregnancy can cause embryo-fetal harm; advise of risk and need for effective contraception.
注意が必要な方
- Severe, life-threatening and fatal diarrhea can occur despite loperamide prophylaxis; higher risk with tislelizumab and in patients aged 65 years or older.
- Left ventricular dysfunction: assess LVEF before starting and at regular intervals; safety not established with baseline LVEF below 50%.
- Infusion-related reactions: premedicate, monitor, slow or stop infusion; permanently discontinue for recurrent severe or life-threatening IRRs.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (1)
- Fluorouracil + Zanidatamab Moderate
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Zanidatamabの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Zanidatamab used for?
Zanidatamab is a medicine in the class oncology. It is used for Biliary tract cancers, Gastric cancer.
What side effects have been reported with Zanidatamab?
Diarrhea, Nausea, Decreased appetite, Vomiting, Hypokalemia, Fatigue. Serious warning: With fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life-threatening and fatal cases.
Can Zanidatamab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm; not recommended during pregnancy. HER2-directed antibodies have caused oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death. Breastfeeding: Unknown. No data on presence in human milk or effects on infant. Weigh benefits of breastfeeding against clinical need; consider half-life of about 24 days and 4-month washout.
What does Zanidatamab interact with?
MediHelp lists 1 known interactions for Zanidatamab. Moderate: 1. The most serious include Fluorouracil.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
